Also this MBL technology can provide antibodies with extremely high binding affinity.ġ) Suematsu S. In monoclonal antibody-production using this technology, the number of monoclonal antibodies obtained is more than 10 times larger than what can be done by conventional methods. When artificial lymph nodes formed in immunized mice are transplanted into immunodeficient mice, they are capable of producing an antibody titer for target antigens that is 10 to 100 times higher than that in normal mice. Normal lymph nodes contain immune cells that respond to various antigens, whereas artificial lymph nodes have a distinct feature in that they consist of only targeting antigen-specific immune cells. The technology was developed for the preparation of artificial lymph nodes in the kidney of mice. MBL’s artificial lymph node technology is a highly efficient antibody-production technology based on the method created by Professor Takeshi Watanabe at the National Research and Development Institute, RIKEN, and his associates. Recombinant Protein Production Technology.SPYMEG, Fusion Partner Cell Line for fully Human Monoclonal Antibodies.Production of Human Monoclonal Antibodies by Phage Display Method.Human Monoclonal Antibody-Producing Technology.
ANTIBODY PRODUCTION FREE
Injection sites should be clean and free of debris, but need not be aseptically prepared.Millipore filtration of the antigen prior to mixing with adjuvant is recommended. The inoculum should be free of extraneous microbial contamination.The veterinary staff must be contacted should any of these symptoms occur. Animals must be observed for evidence of pain, distress or infection resulting from the injection.
The veterinary staff must be contacted if any of these symptoms occur.
ANTIBODY PRODUCTION SKIN
Intradermal injections can cause skin ulceration and necrosis.
Ascites fluid should not exceed 20% of the baseline body weight.Subsequent harvesting shall be performed as a terminal procedure. Ascites fluid may be harvested only once with recovery of the animal.Animals must be anesthetized prior to peritoneal tap.Fluid should be removed before abdominal distension is great enough to cause discomfort, or labored breathing, or to interfere with normal activity.Animals must be observed at least three times per week the first week, and daily thereafter, including weekends and holidays, to monitor the degree of abdominal distension, to relieve it as needed, and to look for other signs of illness.No more than 0.1 ml Pristane, or 0.25 ml Freund's Incomplete Adjuvant, may be used for peritoneal cavity priming.Justification for the in-house production of antibodies may not be based on cost or convenience. The proposed antibody is not commercially available and/or commercially available alternatives are not suitable for the research objectives.Use of the ascites method for production of antibodies in a live animal requires strong scientific justification and adherence to the following guidelines:
0 kommentar(er)
